Abstract
It has been reported that AGEs and the receptor for AGEs (RAGEs) have been linked to the pathogenesis of diabetic microangiopathy. However, the relationship between RAGE and alteration in bone metabolism is unclear. Therefore, in order to determine the role of RAGE in bone metabolism, we investigated the effects of RAGE deletion on bone metabolism under physiological and diabetic conditions using RAGE knockout mice (RAGE-KO). Eight-week-old male RAGE-KO and wild-type littermates (WT) were intraperitoneally injected with either streptozotocin or vehicle. Mice were classified into four groups: (1) nondiabetic WT; (2) nondiabetic RAGE-KO; (3) diabetic WT; and (4) diabetic RAGE-KO. After 12 weeks of streptozotocin or vehicle treatment, the physical properties of femora and the static and dynamic parameters of bone histomorphometry of tibiae were assessed. The deletion of RAGE affected neither body weights nor hemoglobin A1c levels. RAGE deletion resulted in increased bone mineral density due to decreased osteoclast function under physiological conditions that is no accumulation of AGEs. In contrast, lacking RAGE did not affect the alteration in bone metabolism under diabetic conditions, suggesting that AGEs–RAGE interaction may not be involved in the pathogenesis of diabetic osteopenia, although RAGE plays a crucial role in bone metabolism.
Similar content being viewed by others
References
M.E. Levin, V.C. Boisseau, L.V. Avioli, Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes. N. Engl. J. Med. 294(5), 241–245 (1976)
L. Forsén, H.E. Meyer, K. Midthjell, T.H. Edna, Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trøndelag Health Survey. Diabetologia 42(8), 920–925 (1999)
A.M. Herskind, K. Christensen, K. Nørgaard-Andersen, J.F. Andersen, Diabetes mellitus and healing of closed fractures. Diabete Metab 18(1), 63–64 (1992)
Y. Hamada, S. Kitazawa, R. Kitazawa, H. Fujii, M. Kasuga, M. Fukagawa, Histomorphometric analysis of diabetic osteopenia in streptozotocin-induced diabetic mice: a possible role of oxidative stress. Bone 40(5), 1408–1414 (2007)
H. Fujii, Y. Hamada, M. Fukagawa, Bone formation in spontaneously diabetic Torii-newly established model of non-obese type 2 diabetes rats. Bone 42(2), 372–379 (2008)
Y. Hamada, H. Fujii, R. Kitazawa, J. Yodoi, S. Kitazawa, M. Fukagawa, Thioredoxin-1 overexpression in transgenic mice attenuates streptozotocin-induced diabetic osteopenia: a novel role of oxidative stress and therapeutic implications. Bone 44(5), 936–941 (2009)
Y. Hamada, H. Fujii, M. Fukagawa, Role of oxidative stress in diabetic bone disorder. Bone 45(Suppl 1), S35–S38 (2009)
M. Brownlee, Biochemistry and molecular cell biology of diabetic complications. Nature 414(6865), 813–820 (2001)
T. Miyata, K. Notoya, K. Yoshida, K. Horie, K. Maeda, K. Kurokawa et al., Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J. Am. Soc. Nephrol. 8(2), 260–270 (1997)
M. Alikhani, Z. Alikhani, C. Boyd, C.M. MacLellan, M. Raptis, R. Liu et al., Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone 40(2), 345–353 (2007)
G. Hein, R. Wiegand, G. Lehmann, G. Stein, S. Franke, Advanced glycation end-products pentosidine and N epsilon-carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology 42(10), 1242–1246 (2003)
M. Shiraki, T. Kuroda, S. Tanaka, M. Saito, M. Fukunaga, T. Nakamura, Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures. J. Bone Miner. Metab. 26(1), 93–100 (2008)
A.M. Schmidt, M. Vianna, M. Gerlach, J. Brett, J. Ryan, J. Kao et al., Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem. 267(21), 14987–14997 (1992)
M. Neeper, A.M. Schmidt, J. Brett, S.D. Yan, F. Wang, Y.C. Pan et al., Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267(21), 14998–15004 (1992)
J. Brett, A.M. Schmidt, S.D. Yan, Y.S. Zou, E. Weidman, D. Pinsky et al., Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol. 143(6), 1699–1712 (1993)
A.M. Schmidt, S.D. Yan, D.M. Stern, The dark side of glucose. Nat. Med. 1(10), 1002–1004 (1995)
W.F. Owen Jr., F.F. Hou, R.O. Stuart, J. Kay, J. Boyce, G.M. Chertow et al., β2-Microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts. Kidney Int. 53(5), 1365–1373 (1998)
S. Kume, S. Kato, S. Yamagishi, Y. Inagaki, S. Ueda, N. Arima et al., Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J. Bone Miner. Res. 20(9), 1647–1658 (2005)
K. Abeyama, D.M. Stern, Y. Ito, K. Kawahara, Y. Yoshimoto, M. Tanaka et al., The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J. Clin. Invest. 115(5), 1267–1274 (2005)
K.M. Myint, Y. Yamamoto, T. Doi, I. Kato, A. Harashima, H. Yonekura et al., RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes 55(9), 2510–2522 (2006)
A.M. Parfitt, M.K. Drezner, F.H. Glorieux, J.A. Kanis, H. Malluche, P.J. Meunier et al., Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2(6), 595–610 (1987)
Z. Zhou, D. Immel, C.X. Xi, A. Bierhaus, X. Feng, L. Mei et al., Regulation of osteoclast function and bone mass by RAGE. J. Exp. Med. 203(4), 1067–1080 (2006)
B.K. Philip, P.J. Childress, A.G. Robling, A. Heller, P.P. Nawroth, A. Bierhaus et al., RAGE supports parathyroid hormone-induced gains in femoral trabecular bone. Am. J. Physiol. Endocrinol. Metab. 298(3), 714–725 (2010)
T. Kislinger, C. Fu, B. Huber, W. Qu, A. Taguchi, S. Du Yan et al., N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem. 274(44), 31740–31749 (1999)
O. Hori, J. Brett, T. Slattery, R. Cao, J. Zhang, J.X. Chen et al., The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 270(43), 25752–25761 (1995)
A. Taguchi, D.C. Blood, G. del Toro, A. Canet, D.C. Lee, W. Qu et al., Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405(6784), 354–360 (2000)
M.A. Hofmann, S. Drury, C. Fu, W. Qu, A. Taguchi, Y. Lu et al., RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97(7), 889–901 (1999)
S.D. Yan, X. Chen, J. Fu, M. Chen, H. Zhu, A. Roher et al., RAGE and amyloid-β peptide neurotoxicity in Alzheimer’s disease. Nature 382(6593), 685–691 (1996)
T. Chavakis, A. Bierhaus, N. Al-Fakhri, D. Schneider, S. Witte, T. Linn et al., The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J. Exp. Med. 198(10), 1507–1515 (2003)
L.G. Bucciarelli, T. Wendt, L. Rong, E. Lalla, M.A. Hofmann, M.T. Goova et al., RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell. Mol. Life Sci. 59(7), 1117–1128 (2002)
A.M. Schmidt, S.D. Yan, J.L. Wautier, D. Stern, Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res. 84(5), 489–497 (1999)
H. Yonekura, Y. Yamamoto, S. Sakurai, R.G. Petrova, M.J. Abedin, H. Li et al., Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem. J. 370, 1097–1109 (2003)
C. Schlueter, S. Hauke, A.M. Flohr, P. Rogalla, J. Bullerdiek, Tissue-specific expression patterns of the RAGE receptor and its soluble forms—a result of regulated alternative splicing? Biochim. Biophys. Acta 1630(1), 1–6 (2003)
Q. Ding, J.N. Keller, Splice variants of the receptor for advanced glycosylation end products (RAGE) in human brain. Neurosci. Lett. 373(1), 67–72 (2005)
A. Bierhaus, P.M. Humpert, M. Morcos, T. Wendt, T. Chavakis, B. Arnold et al., Understanding RAGE, the receptor for advanced glycation end products. J. Mol. Med. 83(11), 876–886 (2005)
E. Lalla, I.B. Lamster, M. Feit, L. Huang, A. Spessot, W. Qu et al., Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J. Clin. Invest. 105(8), 1117–1124 (2000)
J.L. Wautier, C. Zoukourian, O. Chappey, M.P. Wautier, P.J. Guillausseau, R. Cao et al., Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J. Clin. Invest. 97(1), 238–243 (1996)
L. Park, K.G. Raman, K.J. Lee, Y. Lu, L.J. Ferran Jr., W.S. Chow et al., Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 4(9), 1025–1031 (1998)
Acknowledgments
This study is supported in part by a grant from the Kidney Foundation of Japan (JKFB09-16; YH), and Grant-in-Aid for Young Scientists (B) (22790790; YH) and the 21st Century COE Program “Center of Excellence for Signal Transduction Disease: Diabetes Mellitus as Model” (MF and SK) by the Ministry of Education, Culture, Sports, Science, and Technology of Japan. We are grateful to Kureha Special Laboratory Co. Ltd. for technical assistance. We also thank S. Matsuda and R. Sadato (Kobe University School of Medicine) for their technical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hamada, Y., Kitazawa, S., Kitazawa, R. et al. The effects of the receptor for advanced glycation end products (RAGE) on bone metabolism under physiological and diabetic conditions. Endocr 38, 369–376 (2010). https://doi.org/10.1007/s12020-010-9390-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-010-9390-9